Literature DB >> 8230450

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.

J E Fitzgibbon1, A E Farnham, S J Sperber, H Kim, D T Dubin.   

Abstract

Multiple mutations were found in the human immunodeficiency virus pol gene following treatment of an AIDS patient with antiretroviral drugs. After approximately 2.5 years of monthly alternating therapy with 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), most of the pol sequences amplified from the patient's peripheral blood mononuclear cell DNA contained known AZT resistance mutations at codons 41, 67, and 215 and a putative ddC resistance mutation at codon 69 as well as other novel mutations. These mutations persisted for 6 months after the patient was switched to 2',3'-dideoxyinosine monotherapy. Mutations known to be associated with 2',3'-dideoxyinosine resistance did not occur during this time. Antiviral susceptibility testing of point mutants, introduced into the genetic background of laboratory strain NL4-3, showed that the codon 41 mutation antagonized ddC resistance when present with the codon 69 mutation. However, this antagonism was not found with a chimeric mutant containing the patient's pol gene sequence from codons 25 to 218, implying that other mutations compensated for the antagonism. Thus, alternating therapy with AZT and ddC resulted in the selection of viruses resistant to both drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230450      PMCID: PMC238190     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.

Authors:  M A Fischl; D D Richman; D M Causey; M H Grieco; Y Bryson; D Mildvan; O L Laskin; J E Groopman; P A Volberding; R T Schooley
Journal:  JAMA       Date:  1989-11-03       Impact factor: 56.272

2.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

3.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

4.  Production of single-stranded plasmid DNA.

Authors:  J Vieira; J Messing
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Authors:  R Rooke; M Tremblay; H Soudeyns; L DeStephano; X J Yao; M Fanning; J S Montaner; M O'Shaughnessy; K Gelmon; C Tsoukas
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

6.  Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.

Authors:  T C Merigan; G Skowron; S A Bozzette; D Richman; R Uttamchandani; M Fischl; R Schooley; M Hirsch; W Soo; C Pettinelli
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

7.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

8.  Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.

Authors:  G Skowron; S A Bozzette; L Lim; C B Pettinelli; H H Schaumburg; J Arezzo; M A Fischl; W G Powderly; D J Gocke; D D Richman; J C Pottage; D Antoniskis; G F McKinley; N E Hyslop; G Ray; G Simon; N Reed; M L LoFaro; R B Uttamchandani; L D Gelb; S J Sperber; R L Murphy; J M Leedom; M H Grieco; J Zachary; M S Hirsch; S A Spector; J Bigley; W Soo; T C Merigan
Journal:  Ann Intern Med       Date:  1993-03-01       Impact factor: 25.391

9.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

View more
  11 in total

Review 1.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 4.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Evolution of the human immunodeficiency virus envelope gene is dominated by purifying selection.

Authors:  C T T Edwards; E C Holmes; O G Pybus; D J Wilson; R P Viscidi; E J Abrams; R E Phillips; A J Drummond
Journal:  Genetics       Date:  2006-09-01       Impact factor: 4.562

7.  Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.

Authors:  Mary Kearney; Jon Spindler; Wei Shao; Frank Maldarelli; Sarah Palmer; Shiu-Lok Hu; Jeffrey D Lifson; Vineet N KewalRamani; John W Mellors; John M Coffin; Zandrea Ambrose
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

8.  Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.

Authors:  P R Harrigan; I Kinghorn; S Bloor; S D Kemp; I Nájera; A Kohli; B A Larder
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  HIV Genetic Diversity and Drug Resistance.

Authors:  André F Santos; Marcelo A Soares
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

Review 10.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.